Sanofi's Lunsekimig Drug Shows Positive Results in Asthma and CRSwNP Trials

Sanofi announced that its drug lunsekimig successfully met primary and key secondary endpoints in its Phase 2 trials for both Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).